checkAd

    EQS-News  4754  0 Kommentare NeuroRx and Relief announce topline efficacy data from patients treated with RLF-100(TM) (aviptadil) under the U.S. FDA Expanded Access Protocol authorization for respiratory failure related to critical COVID-19 - Seite 6


     
    End of News EQS Group News Service

    1140308  13.10.2020 

    fncls.ssp?fn=show_t_gif&application_id=1140308&application_name=news&site_id=wallstreet

    Lesen Sie auch


    EQS Group AG
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 6 von 6

    Verfasst von EQS Group AG
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    EQS-News NeuroRx and Relief announce topline efficacy data from patients treated with RLF-100(TM) (aviptadil) under the U.S. FDA Expanded Access Protocol authorization for respiratory failure related to critical COVID-19 - Seite 6 EQS Group-News: Relief Therapeutics Holdings AG / Key word(s): Study results NeuroRx and Relief announce topline efficacy data from patients treated with RLF-100(TM) (aviptadil) under the U.S. FDA Expanded Access Protocol authorization for …